HyperSpectral Raises $7M Series A-2 to Scale AI-Powered Spectral Intelligence Platform
HyperSpectral, an Alexandria, VA–based startup combining spectroscopy and artificial intelligence, has secured US$7 million in a Series A‑2 funding round aimed at accelerating growth and preparing for a potential Series B in 2026. The round was co‑led by RRE Ventures and Kibo Ventures, with new participation from Avalanche Thinking. As part of the new investment, Avalanche Thinking’s Chairman and CEO, Dr. Vincent D. (Chuck) Mattera, joined HyperSpectral’s board as Chairman.
HyperSpectral first emerged from stealth in mid‑2024 after raising an earlier Series A of US$8.5 million, also led by RRE Ventures and Kibo Ventures, with support from Correlation Ventures and GC&H Investments. That round funded initial development of the company’s spectral‑AI platform and enabled building out its core team and dataset infrastructure.
The company’s flagship product, SpecAI™, is a hardware‑agnostic spectral‑intelligence platform that combines spectroscopy — measuring absorption and emission patterns of light — with advanced AI algorithms trained on proprietary spectral datasets. This allows rapid, non‑invasive detection and classification of particles, pathogens, chemicals, and materials — offering real‑time spectral analytics that can substitute traditional lab-based testing in many cases.
Since its public launch, SpecAI™ has gained considerable recognition: in 2025 it was named a finalist for an R&D 100 Award and won a top honor in the software category at the 2025 Globee Awards under “Disruptive Startup of the Year.” Its success has drawn attention from industries including food safety, medical diagnostics, industrial materials testing, and defense, where rapid, reliable detection of contaminants or threats is critical.
With the fresh funding, HyperSpectral plans to deepen development of its spectral‑AI technology, expand partnerships, and scale commercialization efforts. The added leadership from Chuck Mattera — former CEO of a major photonics company — is seen as a strategic move to strengthen HyperSpectral’s governance and accelerate its push into industrial, biotech, and defense markets.
Company leadership says the capital will be used to extend the platform’s capabilities, build larger and more diverse spectral datasets through lab partnerships and testing collaborations, and prepare infrastructure for larger-scale deployments. This will include expanding the engineering and science teams, and accelerating go‑to‑market operations to meet demand across multiple sectors seeking fast, accurate spectral intelligence.
In early deployments, HyperSpectral highlights that SpecAI™ can detect bacteriological pathogens and contaminants in minutes — without specialized lab preparation — offering major advantages in cost, speed, and reliability compared to traditional lab tests. This capability could transform safety protocols in food processing, healthcare diagnostics, material quality control, and environmental monitoring.
As spectral‑AI emerges as a promising intersection of physics and machine learning, HyperSpectral’s progress and funding reinforce growing investor confidence in the technology’s potential — not just for niche lab applications, but as broadly deployable, real-world diagnostic and detection infrastructure. With a strengthened board, deeper technical roadmap, and fresh capital, HyperSpectral is positioning itself to deliver “spectral intelligence at scale,” potentially reshaping how industries detect invisible threats and ensure safety across food, health, manufacturing, and defense.
